4ja9
From Proteopedia
Rat PP5 apo
Structural highlights
Function[PPP5_RAT] Serine/threonine-protein phosphatase that dephosphorylates a myriad of proteins involved in different signaling pathways including the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT. Implicated in wide ranging cellular processes, including apoptosis, differentiation, DNA damage response, cell survival, regulation of ion channels or circadian rhythms, in response to steroid and thyroid hormones, calcium, fatty acids, TGF-beta as well as oxidative and genotoxic stresses. Participates in the control of DNA damage response mechanisms such as checkpoint activation and DNA damage repair through, for instance, the regulation ATM/ATR-signaling and dephosphorylation of PRKDC and TP53BP1. Inhibits ASK1/MAP3K5-mediated apoptosis induced by oxidative stress. Plays a positive role in adipogenesis, mainly through the dephosphorylation and activation of PPARG transactivation function. Also dephosphorylates and inhibits the anti-adipogenic effect of NR3C1. Regulates the circadian rhythms, through the dephosphorylation and activation of CSNK1E. May modulate TGF-beta signaling pathway by the regulation of SMAD3 phosphorylation and protein expression levels. Dephosphorylates and may play a role in the regulation of TAU/MAPT. Through their dephosphorylation, may play a role in the regulation of ions channels such as KCNH2.[1] [2] [3] [4] [5] Publication Abstract from PubMedProtein phosphatase 5 (PP5) is an evolutionary conserved serine/threonine phosphatase that is autoregulated by its Hsp90-interacting tetratricopeptide repeat (TPR) domain and its C-terminal alphahelix. PP5-catalyzed dephosphorylation modulates a diverse set of cellular factors including protein kinases and the microtubule-associated tau-protein involved in neurodegenerative disorders. Here, we report the identification of five specific PP5 activators (P5SAs) that enhance the phosphatase activity up to 8-fold. The compounds are allosteric modulators accelerating exclusively the turnover rate of PP5, but do not affect substrate binding or the interaction between PP5 and the chaperone Hsp90. Functional studies imply a binding site in the phosphatase domain and crystallographic comparisons of the apo PP5 and the PP5:P5SA-2 complex indicate a relaxation of the autoinhibited state of PP5 upon activator binding to the phosphatase-TPR domain interface. Mutations in this site suppress the activatory potential of the ligands. Thus, these compounds may be able to target a regulatory pocket at the domain interface of the PP5 enzyme and serve as a starting point to develop optimized activators based on these scaffolds. Selective activators of protein phosphatase 5 target the autoinhibitory mechanism.,Haslbeck V, Drazic A, Eckl JM, Alte F, Helmuth M, Popowicz G, Schmidt W, Braun F, Weiwad M, Fischer G, Gemmecker G, Sattler M, Striggow F, Groll M, Richter K Biosci Rep. 2015 Apr 20. PMID:25892015[6] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||||||||
Categories: Buffalo rat | Phosphoprotein phosphatase | Alte, F | Fischer, G | Gemmecker, G | Groll, M | Haslbeck, V | Helmuth, M | Popowicz, G | Richter, K | Sattler, M | Schmidt, W | Striggow, F | Weiwad, M | Activation | Hsp90 | Hydrolase | Neurodegenerative disease | Pp5 | Ser/thr-protein phosphatase domain | Tau-dephosphorylation | Tetratricopeptide repeat domain
